Literature DB >> 28453472

The 2002 NIMH Provisional Diagnostic Criteria for Depression of Alzheimer's Disease (PDC-dAD): Gauging their Validity over a Decade Later.

Amir A Sepehry1,2,3, Philip E Lee2,3,4, Ging-Yuek R Hsiung1,2,3, B Lynn Beattie3,4, Howard H Feldman2,3,5, Claudia Jacova1,2,3.   

Abstract

Presented herein is evidence for criterion, content, and convergent/discriminant validity of the NIMH-Provisional Diagnostic Criteria for depression of Alzheimer's Disease (PDC-dAD) that were formulated to address depression in Alzheimer's disease (AD). Using meta-analytic and systematic review methods, we examined criterion validity evidence in epidemiological and clinical studies comparing the PDC-dAD to Diagnostic and Statistical Manual of Mental Disorders fourth edition (DSM-IV), and International Classification of Disease (ICD 9) depression diagnostic criteria. We estimated prevalence of depression by PDC, DSM, and ICD with an omnibus event rate effect-size. We also examined diagnostic agreement between PDC and DSM. To gauge content validity, we reviewed rates of symptom endorsement for each diagnostic approach. Finally, we examined the PDC's relationship with assessment scales (global cognition, neuropsychiatric, and depression definition) for convergent validity evidence. The aggregate evidence supports the validity of the PDC-dAD. Our findings suggest that depression in AD differs from other depressive disorders including Major Depressive Disorder (MDD) in that dAD is more prevalent, with generally a milder presentation and with unique features not captured by the DSM. Although the PDC are the current standard for diagnosis of depression in AD, we identified the need for their further optimization based on predictive validity evidence.

Entities:  

Keywords:  Alzheimer’s disease; DSM; NIMH Provisional Diagnostic Criteria; depression; diagnosis; epidemiology; meta-analysis; validity

Mesh:

Year:  2017        PMID: 28453472     DOI: 10.3233/JAD-161061

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  2 in total

1.  A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms.

Authors:  Katy Bernard; Sylvie Gouttefangeas; Sylvie Bretin; Stéphanie Galtier; Philippe Robert; Vjera Holthoff-Detto; Jeffrey Cummings; Maria Pueyo
Journal:  Alzheimers Dement (N Y)       Date:  2019-06-24

Review 2.  The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative Diseases.

Authors:  Jeffrey Cummings
Journal:  Am J Geriatr Psychiatry       Date:  2020-07-27       Impact factor: 4.105

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.